Form 4: ClearPoint Neuro CFO Danilo D'Alessandro Reports Stock Acquisition Under Employee Stock Purchase Plan

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports acquiring 1,949 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.53 per share.

Summary

• Danilo D'Alessandro, CFO of ClearPoint Neuro, Inc., filed a Form 4 on January 3, 2025, reporting a transaction.
• On December 31, 2024, D'Alessandro acquired 1,949 shares of ClearPoint Neuro common stock.
• The acquisition was made through the company's Employee Stock Purchase Plan (ESPP).
• The price per share was $4.53.
• Following the transaction, D'Alessandro beneficially owns 51,441 shares of ClearPoint Neuro common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction under the company's ESPP. The CFO's participation is a positive signal, but it's not a major event.

Positives

• The CFO's participation in the ESPP demonstrates confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CFO's participation in the company's ESPP, which is a common benefit offered by publicly traded companies.

Comparison to Industry Standards

• ESPP programs are common across publicly traded companies, with discount rates typically ranging from 5% to 15% of the market price.
• Insider transactions are closely monitored and reported to the SEC to ensure fair market practices.
• Comparable companies in the medical device industry also have similar insider trading policies and ESPP programs.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a key executive.

Key Dates